Role of Faascin protein in proliferation and invasion of hepatocellular carcinoma.

Faascin 蛋白在肝细胞癌增殖和侵袭中的作用。

• 批准号: 20591614
• 负责人: TAKETOMI Akinobu
• 金额: $ 2.91万
• 依托单位: Kyushu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591614/
• 关键词: Fascin; 肝細胞癌; 予後; 無再発生存; 浸潤; 転移

BACKGROUND : Fascin is an actin-bundling protein and induces membrane protrusions and cell motility after the formation of lamellipodia or filopodia. Fascin expression has been reported to be associated with progression or prognosis in various neoplasms, but the role of fascin in hepatocellular carcinoma (HCC) remains unknown. The aim of this study was to investigate the clinicopathological and prognostic relevance of fascin by immunohistochemistry. METHODS : A total of 137 patients with HCC were stained with anti-fascin antibody. The tumor cells having unequivocal cytoplasmic and/or membranous fascin immunoreactivity were defined as fascin-positive. RESULTS : Immunohistochemically, 23 (16.8%) HCCs having unequivocal fascin immunoreactivity were found. Tumors showing fascin expression were larger and less differentiated than those showing no fascin expression (P=0.0239 and 0.0018, respectively). Portal venous invasion, bile duct invasion, and intrahepatic metastasis were detected significantly more frequently in fascin-positive group (P=0.0029, 0.0333, and 0.0403, respectively). In addition, high alpha-fetoprotein (AFP) levels were significantly associated with the fascin expression in HCC (P=0.0116). Fascin-positive group had significantly poorer outcomes than fascin-negative group and was an independent prognostic factor for disease-free survival. CONCLUSIONS : Fascin might become a novel marker of progression in HCC and a significant indicator of a poor prognosis for patients with HCC.

背景：肌成束蛋白是一种肌动蛋白成束蛋白，在板状伪足或丝状伪足形成后诱导膜突出和细胞运动。据报道，肌成束蛋白的表达与各种肿瘤的进展或预后相关，但肌成束蛋白在肝细胞癌（HCC）中的作用仍不清楚。本研究的目的是通过免疫组织化学研究肌成束蛋白的临床病理学和预后相关性。方法：对137例HCC患者进行抗肌成束蛋白抗体染色。具有明确的细胞质和/或膜肌成束蛋白免疫反应性的肿瘤细胞被定义为肌成束蛋白阳性。结果：免疫组织化学发现 23 个 (16.8%) HCC 具有明确的肌成束蛋白免疫反应性。显示肌成束蛋白表达的肿瘤比不显示肌成束蛋白表达的肿瘤更大且分化程度更低（分别P=0.0239和0.0018）。肌成束蛋白阳性组门静脉侵犯、胆管侵犯和肝内转移的发生率显着更高（P分别为0.0029、0.0333和0.0403）。此外，高甲胎蛋白 (AFP) 水平与 HCC 中肌成束蛋白的表达显着相关 (P=0.0116)。肌成束蛋白阳性组的预后明显差于肌成束蛋白阴性组，并且是无病生存的独立预后因素。结论：Fascin 可能成为 HCC 进展的新标志物，也是 HCC 患者预后不良的重要指标。

项目成果

Stage IV肝細胞癌に対する治療戦略決定のための予後予測システムの構築

IV期肝细胞癌治疗策略的预后预测系统的构建

• 发表时间: 2009
• 作者: 武冨紹信;森田和豊;梅田健二;永田茂行;杉町圭史;池上徹;祇園智信;副島雄二;調憲;前原喜彦
• 通讯作者: 前原喜彦

The impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.

脱γ-羧基凝血酶原和肿瘤大小对活体肝移植后肝细胞癌复发的影响。

• 发表时间: 2009
• 期刊: Transplantation 87(4)
• 作者: Taketomi A;Sanefuji K;Soejima Y;Yoshizumi T;Uhciyama H;Ikegami T;Harada N;Yamashita Y;Sugimachi K;Kayashima H;Iguchi T;Maehara Y.
• 通讯作者: Maehara Y.

ウイルスおよび宿主の遺伝子解析による肝移植後再発C型肝炎に対する高精度なIFN治療効果予測

利用病毒和宿主基因分析高度准确预测干扰素对肝移植后复发性丙型肝炎的治疗效果

• 发表时间: 2010
• 作者: 武冨紹信;他
• 通讯作者: 他

再発肝細胞癌に対する生体肝移植の治療成績

活体肝移植治疗复发性肝癌的效果

• 发表时间: 2010
• 作者: 武冨紹信;他
• 通讯作者: 他

肝左葉グラフトを第一選択とする生体肝移植ドナー選択基準の意義

以左肝叶为首选的活体肝移植供体选择标准的意义

• 发表时间: 2010
• 作者: 武冨紹信;他
• 通讯作者: 他